Ziemer takes Amadeus back from AMO

Article

The Ziemer group is to assume all worldwide marketing, sales and support duties for AMO's Amadeus II automated microkeratome.

The Ziemer group is to assume all worldwide marketing, sales and support duties for AMO's Amadeus II automated microkeratome.

The Amadeus product line was originally developed by a subsidiary of Ziemer and the rights were sold to AMO in 1999. Ziemer has since developed a global marketing and distribution network that it can rely on to market the Amadeus.

Ziemer also sells the Femto LDV femtosecond laser, making it the only ophthalmic company to offer a choice of microkeratome or femstosecond lasers for corneal refractive surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
A row of beakers with yellow and orange fluid in a laboratory. Concept image for microbial lutein production, bioengineering, sustainable synthesis for cataract cornea age-related macular degeneration (AMD) and retinal disease. Image credit: bidala – stock.adobe.com

New microbial strain produces high yields of lutein for AMD, cataract prevention

Kassi Filkins
July 15th 2025
Article

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Jordana Joy
July 12th 2025
Article

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Health Canada approves aflibercept biosimilar Aflivu

Health Canada approves aflibercept biosimilar Aflivu

Sydney M Crago
July 10th 2025
Article

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

A Canadian flag in front of a mountain range. Concept image for Alcon Clareon Panoptix Pro intraocular lens IOL launch and approval in Canada. Image credit: ©toptop54 from pixabay - Canva.com

Clareon Panoptix Pro IOL (Alcon) approved in Canada

Jordana Joy
July 9th 2025
Article

The trifocal IOL is designed to deliver lower light scatter and higher-reported light utilisation

A close up of an eye with a brown iris, concept image for diabetic retinopathy and glaucoma research. Image credit: ©Made in Uruguay from Pexels – Canva.com

Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001

Sydney M Crago
July 9th 2025
Article

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

© 2025 MJH Life Sciences

All rights reserved.